0000920465-20-000039.txt : 20200303 0000920465-20-000039.hdr.sgml : 20200303 20200303161425 ACCESSION NUMBER: 0000920465-20-000039 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200228 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolke James CENTRAL INDEX KEY: 0001693858 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 20682383 MAIL ADDRESS: STREET 1: 10182 TELESIS COURT, 6TH FLOOR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_158327004839858.xml FORM 4 X0306 4 2020-02-28 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001693858 Rolke James C/O LA JOLLA PHARMACEUTICAL COMPANY, 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121 0 1 0 0 Chief Scientific Officer Common Stock 2020-02-28 4 A 0 142 5.78 A 80677 D Stock Option (Right to Buy) 6.8 2020-02-28 4 A 0 142 0 A 2030-02-28 Common Stock 142.0 142 D These shares were acquired on 02/28/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. /s/ Ryan Murr, as attorney-in-fact for James Rolke 2020-03-03